Ask AI
Moderate to Severe Atopic Dermatitis Treatment Selection
Individualizing Therapy for Patients With Moderate to Severe Atopic Dermatitis While Emphasizing the Importance and Role of Biologics

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: June 19, 2025

Expiration: June 18, 2026

About This Tool & Disclaimer

Individualizing Therapy for Patients With Moderate to Severe Atopic Dermatitis While Emphasizing the Importance and Role of Biologics 

Clinical Care Options, LLC, is grateful to Daniel Butler, MD; Peter Lio, MD, FAAD; Jennifer Schoch, MD, FAAD; Benjamin Ungar, MD; and Gil Yosipovitch, MD, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in May 2025 and reflects the guidelines available at that time.

The goal of the tool is to educate clinicians on making optimal management choices for managing patients with moderate-to-severe atopic dermatitis (AD) based on current AAD practice guidelines in the United States.

A series of questions allow the participant to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include age, desire to become pregnant or current pregnancy status, treatment preference, comfort with maintenance labs, concomitant medications, and comorbid conditions.

It should be noted that these are not exclusive characteristics when selecting optimal treatment for patients with moderate-to-severe AD. Other considerations that are not included in this tool, such as the specific subtype of moderate-to-severe AD, should also be considered, when appropriate for making management decisions.

This tool assumes we have a “standard” patient with moderate-to-severe AD but with no additional features or specific comorbidities that would affect treatment choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display guideline- and expert-based recommendations for that specific patient case.

This program is supported by an educational grant from Lilly.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Daniel Butler, MD, has disclosed that he has received funds to serve as a consultant/advisor/speaker for AbbVie, Galderma, and Leo.

Peter Lio, MD, FAAD has disclosed that he has received funds to serve as a consutant/advisor/speaker for AbbVie, Almirall, Alphyn Biologics, Amyris, Arcutis, ASLAN, Astria Therapeutics, Boston Skin Science, Bristol-Myers Squibb, Burt’s Bees, Castle Biosciences, Codex Labs, Concerto Biosciences, Dermavant, Galderma, LEO Pharma, Lilly, Lipidor, L’Oreal, Merck, Micreos, MyOR Diagnostics, Pelthos Therapeutics, Regeneron/Sanofi Genzyme, Sibel Health, Skinfix, Soteri Skin, Stratum Biosciences, Sun Pharma, Theraplex, Thimble Health, UCB, Unilever, Verdant Scientific, Verrica; has individually publicly traded stocks/stock options with Alphyn Labs, Codex Labs, Concerto Biosciences, Soteri Skin, Stratum Biosciences, Thimble, Yobee Care; and has received royalties/patent beneficiary with Theraplex AIM.

Jennifer Schoch, MD, FAAD has no relevant financial relationships to disclose.

Benjamin Ungar, MD has disclosed that he has received funds to serve as a consultant/advisor/speaker for AbbVie, Botanix, Bristol Myers Squibb, Fresenius Kabi, Galderma, Johnson & Johnson, LEO Pharma, Lilly, Pfizer, Primus, Sanofi, UCB; researcher for Incyte, Rapt Therapeutics, and Sanofi.

Gil Yosipovitch, MD has disclosed that he has received funds to serve as a consultant/advisor/speaker for AbbVie, Arcutis, Almiral, Amgen, Celldex, Escient, Galderma, GlaxoSmithKline, LEO Pharma, Lilly, Merck, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi, Vifor; researcher: AbbVie, Celldex, Escient, Galderma, Kiniksa, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi.

© 2025 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Individualizing Therapy for Patients With Moderate to Severe Atopic Dermatitis While Emphasizing the Importance and Role of Biologics ” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices for managing individuals with moderate-to-severe atopic dermatitis (AD). The information provided is based on the AAD guideline recommendations and expert guidance of Daniel Butler, MD; Peter Lio, MD, FAAD; Jennifer Schoch, MD, FAAD; Benjamin Ungar, MD; and Gil Yosipovitch, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Individualizing Therapy for Patients With Moderate to Severe Atopic Dermatitis While Emphasizing the Importance and Role of Biologics?” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2025 Clinical Care Options, LLC. All rights reserved.

Program Content